Keros Therapeutics (KROS) is a clinical-stage biopharmaceutical company in Lexington, Massachusetts, developing protein therapeutics that target dysfunctional signaling of the TGF-β family of proteins. Its lead program, rinvatercept, is in Phase 2 testing for Duchenne muscular dystrophy and amyotrophic lateral sclerosis, while elritercept, licensed to Takeda, targets cytopenias in myelodysplastic syndromes and myelofibrosis. On Tuesday the stock rose 13.26% to $11.36, compared with a prior close of $10.03, a gain of $1.33. The advance followed the company's disclosure of a new $5 million share repurchase authorization tied to a fresh $20 million milestone payment, a combination markets read as a signal of balance-sheet confidence from a stock trading below its own cash pile.
The clearest verified catalyst was published after Monday's closing bell: Keros' board approved a stock repurchase program for up to $5 million of common stock. The authorization followed receipt of a $20 million development milestone under the Takeda license agreement, triggered by dosing of the first patient in the ELRiSE MF trial of elritercept.
The dollar amount is small — roughly 2% of the company's market value — and carries no obligation to buy a single share. But the sequencing mattered to investors. Management chose to return capital immediately after a cash inflow rather than hold all of it, and the company reiterated that cash and equivalents of $259.5 million, adjusted for the milestone and buyback, fund operations into 2029. For a name that has burned cash for years, that combination reads as a statement of confidence.
Underlying the buyback is the Takeda partnership, which transfers most elritercept development costs away from Keros while still generating milestone income. The November payment is the latest in a series, and it arrived alongside the first patient dosing in the myelofibrosis study — a reminder that the partnered asset continues to advance without consuming Keros' own budget.
Analyst activity reinforced the tone without driving it. BofA raised its price target on the shares to $18 from $17 while keeping a Neutral rating, a routine model update following third-quarter results. Consensus sits near $20 across seven analysts with a Buy rating, though that target reflects clinical hope rather than near-term earnings power.
The rally also has a mechanical component. Keros closed at $8.98 on November 9, its 52-week low, and remained down more than 50% year to date even after today's advance. With roughly 19.6 million shares outstanding and about $280 million of pro forma cash including the milestone, the equity has been valued at or below its liquid assets — a setup that leaves little room for further pessimism and makes modestly positive news unusually potent. Short interest of about 1.1 million shares, equal to more than seven days of average trading, added fuel to the squeeze.
Volume was clearly elevated: more than 250,000 shares changed hands by mid-afternoon against an average daily turnover near 190,000, a pace of roughly 1.3 times normal, with the heaviest blocks printing in the final hours of the session as the stock pushed from $11.12 toward $11.35.
The move was idiosyncratic. The S&P 500 fell more than 1%, the Russell 2000 dropped about 1.4%, and the major biotech ETFs slipped modestly, leaving Keros sharply divergent from both its sector and the broad market. Technically, the stock reclaimed its 20-day and 50-day moving averages in a single session and closed above the $10.70 area that had capped every rally attempt since the post-earnings selloff of November 5, when shares fell 12.7%.
The scale runs from 0 — no meaningful news and a routine move — to 100, representing transformative news alongside an extreme, rare price move. Keros earns 56 out of 100.
The verified news was moderate: a $5 million discretionary buyback and a $20 million partner milestone are meaningful relative to a company of this size but hardly re-rate the pipeline, and the analyst change was routine. The price move, however, was decidedly unusual — about six times the stock's typical daily swing of 2.2% over the past 60 sessions, and no session in that window produced a comparable gain. Strong trading behavior and moderate news combine into a mid-range score.
The calendar is thin until the first half of 2027, when initial Phase 2 data for rinvatercept in Duchenne muscular dystrophy are expected. Regulatory discussions around a planned Phase 2 ALS trial were slated for the second half of 2026, and any update there would be material. Fourth-quarter results are likely to arrive in early March 2027, with attention on cash burn and milestone recognition rather than revenue trends. Investors will also watch whether the buyback is executed in the open market and whether insiders continue selling. The central risk remains binary: a disappointing Duchenne readout would hit a stock whose valuation rests almost entirely on that program, while cash burn and trial-timing slippage remain ongoing uncertainties.
Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in its curated Trending AI Robots section. Bots vary widely by strategy, timeframe, performance metrics, and the symbols they trade, so the featured lineup shifts as market conditions change. Readers looking for systematic approaches to volatile single-stock moves like today's can review the current leaders and compare their track records.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
KROS moved above its 50-day moving average on November 17, 2026 date and that indicates a change from a downward trend to an upward trend. In 37 of 45 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 82%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where KROS's RSI Indicator exited the oversold zone, 26 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.
The Momentum Indicator moved above the 0 level on November 17, 2026. You may want to consider a long position or call options on KROS as a result. In 78 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for KROS just turned positive on November 17, 2026. Looking at past instances where KROS's MACD turned positive, the stock continued to rise in 35 of 44 cases over the following month. The odds of a continued upward trend are 80%.
Following a +19.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where KROS advanced for three days, in 224 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 10-day moving average for KROS crossed bearishly below the 50-day moving average on November 03, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 59%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KROS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
KROS broke above its upper Bollinger Band on November 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for KROS entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.707) is normal, around the industry mean (3.592). P/E Ratio (-2.907) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (19.417) is also within normal values, averaging (442.120).
The Tickeron Price Growth Rating for this company is 55 (best 1 - 100 worst), indicating steady price growth. KROS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KROS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a biopharmaceutical company, which focuses on treatments for rare muscle diseases
Industry Biotechnology